medigraphic.com
ISSN 2225-4676 (Electronic)

2021, Number 3

<< Back

Rev Cubana Neurol Neurocir 2021; 11 (3)

Forty years of cerebrospinal fluid research at The Institute of Neurology and Neurosurgery

González-Quevedo A, Fernández CR, Peña SM, González GS, Menéndez SMC, Betancourt LM, Fernández AI

Language: Spanish
References: 63
Page: 1-26
PDF size: 418.54 Kb.


ABSTRACT

The article aims to describe how the introduction of various techniques for the study of cerebrospinal fluid was developed and the main results in clinical research at the Institute of Neurology and Neurosurgery to date. The introduction of specific techniques for the investigation of cerebrospinal fluid began in the early 1980s, with the immunological study of cerebrospinal fluid. Techniques were included for the determination of total proteins, polyacrylamide gel electrophoresis, quantification of albumin and immunoglobulins G, M and A in cerebrospinal fluid and serum, calculation of dimensional quotients (Q albumin and IgG index) for the evaluation of the functional state of the blood-cerebrospinal fluid barrier and intrathecal IgG synthesis, respectively. The activity of metalloproteinases 2 and 9 in cerebrospinal fluid was also assessed. Recently, isoelectric focusing of CSF was introduced for the more sensitive detection of IgG oligoclonal bands. All this made possible the use of these techniques for the diagnosis and investigation of various neurological diseases with a neuroinflammatory component in our institute and in Neurology services throughout the country, as well as for the evaluation of some clinical trials in diseases of the nervous system with Cuban molecules. On the other hand, with the investigation of neurotransmitter substances and their metabolites, useful information was obtained in the pathophysiological investigation of some neurodegenerative diseases and in the epidemic neuropathy that occurred in the early 1990s. Finally, important research was carried out to obtain normal ranges and patterns in cerebrospinal fluid of the different biomarkers studied in our institute.


REFERENCES

  1. Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, et al. EFNS guidelines on disease-specific CSF investigations. Eur J Neurol. 2009;16:e156-e163.

  2. González-Quevedo A, Fernández R, González S, Suárez I. Evaluation of the blood–cerebrospinal fluid barrier in neurological diseases. In: Montenegro PA, Juárez SM (eds.) The Blood-Brain Barrier: New Research. New York: Nova Science Publishers: 2012. p. 173-200.

  3. Solar P, Zamani A, Kubíčková L, Dubový P, Joukal M. Choroid plexus and the blood-cerebrospinal fluid barrier in disease. Fluids Barriers CNS. 2020;17(1):35. Doi: https://doi.org/10.1186/s12987-020-00196-2

  4. González-Quevedo A, Luis RS, González JN. Electroforesis de proteínas solubles de musculo humano normal en gel de poliacrilamida. Rev Cub Invest Biomed. 1982;1:89-95.

  5. Smith I. Chromatographic and electrophoretic techniques. Vol. II. Zone electrophoresis. Great Britain: Pitman Press; 1968. p. 369-83.

  6. González-Quevedo A, Olivares E, Fernández R, Araña J, González Z. Polyacrylamide gel electrophoresis of unconcentrated cerebrospinal fluid in children. J Neurosci. 1989;49:270.

  7. González-Quevedo A, Fernández Carriera RA, León Ortiz MM, González García S, Vicente Valdés I. Electroforesis de proteínas del líquido cefalorraquídeo normal en niños y adultos. Rev Mex Neuroci. 2008;9(3):242-7.

  8. Lowry OH, Rosebrough RJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-75.

  9. Caballero Poo G, Estrada González R, Villaescusa R. Tratamiento de la polirradiculoneuritis aguda tipo Landry-Guillain-Barré-Strohl con plasmaféresis. Rev Cub Invest Biomed. 1983;2:149-60.

  10. Alfaro Capdegelle I, Díaz Avalos L, Luis González S. Estudios inmunológicos en pacientes afectos de miastenia gravis. Rev Cub Med. 1989;28(1-2):17-27.

  11. Alfaro Capdegelle I, Ortega C, del Pino M, Hernández O, Sánchez JE, González-Quevedo A, et al. Cerebrospinal fluid in patients with epilepsy: some immunological aspects. Acta Neurol Scand. 1990;82(suppl. 133):26.

  12. Pintado A, Alfaro I, del Pino M, Armas A, Hernández-Cossío O. Integrity of the blood brain barrier and anticonvulsant concentration in the CSF. Epilepsia. 1991;32(suppl 1):s115.

  13. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analysis in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977;37:385-90.

  14. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest. 1977;37:397-401.

  15. González-Quevedo A, Fernández Carriera R, Lestayo O´Farrill Z, Suárez Luis I, Mustelier Bécquer R, Luis González RS. An appraisal of blood-cerebrospinal fluid barrier dysfunction during the course of Guillain Barré syndrome. Neurol India. 2009;57(3):288-94.

  16. Cabrera JA, Santana E, Vals O, Casanova M, Alfaro I, González-Quevedo A, et al. Clinical characterization of patients with Multiple Sclerosis defined in Cuba. Rev Neurol 1998;26:723-8.

  17. Cabrera-Gómez JA, Santana-Capote E, Echazabal-Santana N, Casanova M, Gómez I, Ramos AM, et al. Estado actual de la esclerosis múltiple en Cuba. Rev Neurol. 2000;31(5):482-93.

  18. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256(1):35-44.

  19. Cabrera-Lima AV, Estrada R, Santiago-Luis R, Alfaro I, González A, Galarraga-Inza J, et al. Polineuropatía crónica desmielinizante inflamatoria: una contribución a la caracterización de la enfermedad. Rev Neurol. 1999;28:772-8.

  20. González-Quevedo A, Cabrera Gómez JA, Fernández Carriera R, Lestayo O´Farrill Z, González García S, Peña Sánchez M, et al. El empleo del estudio de las proteínas del LCR en enfermedades desmielinizantes del sistema nervioso central y periférico. VIII Congreso Latinoamericano de Esclerosis Múltiple (LACTRIMS). Lima, Perú. 2014 [citado: 14/06/2021]. Disponible en: https://www.researchgate.net/publication/284177326_el_empleo_del_estudio_de_las_proteinas_del_lcr_en_enfermedades_desmielinizantes_del_sistema_nervioso_central_y_periferico

  21. Cabrera Gómez JA, González Quevedo A, Alfaro Capdegelle I, Cabrera Núñez JA. El estudio inmunológico del LCR en la Neuropatía Epidémica. Rev Finlay. 1993;7(1-4):148-56.

  22. Alfaro I, González-Quevedo A, del Pino M, Serrano C, Lara R, González H, et al. Immunoglobulins in epidemic neuropathy in Cuba. J Neurol Sci. 1994;127:234-5.

  23. González-Quevedo A, Fernández Carriera R, Santiesteban Freixas R, Alfaro Capdegelle I, Lara Rodríguez R, Vicente Valdés I, et al. Brain barrier dysfunction in Cuban epidemic optic neuropathy. Eur J Neurol. 2008;15:613-8.

  24. González-Quevedo A, Suárez Luis I, González García S, Fernández Carriera R. Reply to the Letter to the Editor “Cuban Epidemic Optic Neuropathy (CEON) and actual methods to measure immune response in central nervous system”. Eur J Neurol. 2009;16:e47. Doi: 10.1111/j.1468-1331.2008.02426.x.

  25. Fernández Carriera R, González-Quevedo A, Lara Rodríguez R, León Ortiz MM, González García, S, Vicente Valdés I, et al. Electroforesis de proteínas del líquido cefalorraquídeo en pacientes con enfermedad cerebrovascular isquémica. Rev Neurol. 2002;35(10):908-12.

  26. Robinson MA, González-Quevedo A, Lorigados L, Alonso JA, Pavón N, Macías R. Immune system response in Alzheimer's disease. En: Beregi E, Gergeley IA, Rajczi K (Eds). Recent Advances in Aging Science. Bologna: Monduzzi Editore S.p.A.; 1993. p.615- 8.

  27. Cabrera JA, Santana E, Miró A, Gómez A, Echazábal N, Quevedo L, et al. Tratamiento de la Esclerosis Múltiple con Interferón alfa-2b recombinante. Estudio piloto. Biotecnología Aplicada. 1997;14(3):175-80.

  28. González-Quevedo A, Alfaro I, Gámez L, Fernández R, Lara RF, Rodríguez R, et al. Evaluación del líquido cefalorraquídeo en pacientes con Esclerosis Múltiple tratados con Biomodulina T. Rev Mex Neuroci. 2007;8(1):18-22.

  29. Cabrera JA, Cordero JR, Fernández O, Reyes B, Romero K, Simón J, et al. Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2b interferon. Biotherapy. 1993;7(1):27-37.

  30. Suárez-Luis I, Rodríguez-Rodríguez Y, González-Quevedo A, Fernández-Carriera R, Toledano-Pérez M, Rodríguez-Rodríguez PC, et al. Estudio inmunológico del líquido cefalorraquídeo con el empleo de un antisuero de IgG humano producido en Cuba. Evaluación preliminar. Rev Neurol. 2002;35(7):640-3.

  31. Suárez Luis I, Rodríguez Y, González-Quevedo A, Fernández R, Toledano M, Vicente I. Evaluación de un antisuero anti IgG humano por la cuantificación de IgG en suero y LCR. Rev Cub Quím. 2004;16(3):442.

  32. Betancourt Loza M, Cordero Eiriz A, Peña Sánchez M, González García S, Lorigados Pedres L, González–Quevedo A. Cuantificación de la inmunoglobulina G y la albúmina en el líquido cefalorraquídeo mediante las modificaciones de las técnicas para otros fluidos biológicos. Rev Cub Neurol Neuroc. 2016 [citado:14/06/21];6(1):9-16. Disponible en: http://www.revneuro.sld.cu/index.php/neu/article/view/261

  33. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch. Neurol. 2005;62(6):865-70.

  34. Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018;141(4):1075-84.

  35. Betancourt Loza M, Peña Sánchez M, González García S, González-Quevedo A, Fernández I, Peña M, et al. IgG oligoclonal banding in the CSF for differential diagnosis in multiple sclerosis: Experience at the Institute of Neurology and Neurosurgery. Mult Scler J. 2017;23(1):151.

  36. Peña-Sánchez M, Lestayo O´Farril Z, Valido Luna L, González-García S, Betancourt Loza M, Hernández-Díaz ZM, et al. CSF oligoclonal band frequency in a Cuban cohort of patients with Multiple Sclerosis. Comparison with Latin American countries and association with latitude. Mult Scler Rel Dis. 2020;45:102412. Doi: 10.1016/j.msard.2020.102412.

  37. Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult. Scler. 2012;18(7):974-82.

  38. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiat. 2013;84(8):909-14.

  39. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1139-51. Doi: 10.1038/jcbfm.2011.197.

  40. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WG. Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Investig. 1994;71(3):417-22.

  41. Fernández Carriera R, Fernández-Queija L, Lara Rodríguez R, Cabrera Gómez JA, Suárez Luis I, León Ortiz MM, et al. Metaloproteinasas de matriz en pacientes con esclerosis múltiple. Medisur. 2007;5(Especial ECV):51-7.

  42. Bernardo-Castro S, Sousa JA, Brás A, Cecília C, Rodrigues B, Almendra L, et al. Pathophysiology of blood-brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery. Front Neurol. 2020;11:594672. Doi: 10.3389/fneur.2020.594672.

  43. Kurian MA, Gissen P, Smith M, Heales S, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10:721-33.

  44. Brady ST, Tai L. Cell Biology of the Nervous System. In: Brady ST, Siegel GJ, Albers RW, Price DL (eds). Basic Neurochemistry. Principles of molecular, cellular and medical neurobiology. UK: Academic Press, Elsevier; 2012. p. 4-25.

  45. Orozco G, Estrada R, Perry TL, Araña J, Fernández R, González-Quevedo A, et al. Dominantly inherited olivopontocerebellar atrophy from Eastern Cuba. Clinical, neuropathological and biochemical findings. J Neurol Sci. 1989;93:37-52.

  46. González-Quevedo A, García JC, Fernández R, Fernández Cartaya L. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system. Bol Estud Med Biol Mex. 1993;XLI:13-9.

  47. Higgins JJ, Harvey-White JD, Kopin IJ. Low lumbar CSF concentrations of homovanillic acid in the autosomal dominant ataxias. J Neurol Neurosurg Psychiat. 1995;58(6):760. Doi: 10.1136/jnnp.58.6.760

  48. García JC, González-Quevedo A. Decreased CSF monoamine metabolites in patients with Alzheimer’s Disease. Rev CENIC Cienc Biol. 1997;28(1):27-9.

  49. Bonet Roselló L, García Rodríguez JC, McPherson M, Boleda LM, González-Quevedo A, Legrá D. Niveles de los catabolitos de las aminas biógenas en líquido cefalorraquídeo de pacientes con demencia tipo Alzheimer y mixta. Bioquimia. 1998;23(1):801-4.

  50. Llinás S, García JC, Caballero A, Peña LY, Ventura RE, González-Quevedo A, et al. Metabolitos de las monoaminas en líquido cefalorraquídeo de pacientes esquizofrénicos clasificados en síntomas positivos y negativos. Rev Neuropsicofarm Clín. 1996;1(3):9-14.

  51. González-Quevedo A, Obregón F, Santisteban R, Fernández R, Lima L. Los aminoácidos como marcadores bioquímicos en la neuropatía óptica epidémica y endémica. Rev Cub Med Trop. 1998;50(suppl):241-4.

  52. González-Quevedo A, Obregón F, Fernández R, Santiesteban R, Serrano C, Lima L. Amino acid levels and ratios in serum and cerebrospinal fluid of patients with optic neuropathy in Cuba. Nutr Neurosci. 2001;4(1):51-62.

  53. González-Quevedo A, Santiesteban Freixas R, Eells JT, Lima L. Cuban epidemic optic neuropathy. An appraisal of the pathophysiological mechanisms. In: Albin Holmgren and Gerhard Borg (eds). Handbook of Disease Outbreaks: Prevention, Detection and Control. N.Y: Nova Science Publishers; 2010. p. 43-73.

  54. Eells JT, González-Quevedo A, McMartin KE, Sadun A. Folate deficiency and elevated serum and CSF formate concentrations in patients with Cuban epidemic optic neuropathy. Invest Ophthalmol Vis Sci. 1996;37(3):2259.

  55. Eells JT, González-Quevedo A, Santiesteban R, McMartin KE, Sadun A. Deficiencia de folato y concentraciones elevadas de formato en suero y líquido cefalorraquídeo de pacientes con neuropatía óptica epidémica. Rev Cub Med Trop. 2000;52(1):21-3.

  56. Teunissen CE, Tumani H, Engelborghs S, Mollenhauer B. Biobanking of CSF: International standardization to optimize biomarker development. Clin Biochem. 2014;47:288-92. Doi: 10.1016/j.clinbiochem.2013.12.024.

  57. Tigchelaar C, Atmosoerodjo SD, van Faassen M, Wardenaar KJ, De Deyn PP, Schoevers RA, et al. The Anaesthetic Biobank of Cerebrospinal fluid: a unique repository for neuroscientific biomarker research. Ann Transl Med. 2021;9(6):455. Doi: http://dx.doi.org/10.21037/atm-20-4498.

  58. Hegen H, Auer M, Zeileis A, Deisenhammer F. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clin Chem Lab Med. 2016 Feb;54(2):285-92. Doi: 10.1515/cclm-2015-0253.

  59. McCudden CR, Brooks J, Figurado P, Bourque PR. Cerebrospinal fluid total protein reference intervals derived from 20 years of patient data. Clin Chem. 2017;63:1856-65.

  60. Kahlmann V, Roodbol J, van Leeuwen N, Ramakers CRB, van Pelt D, Neuteboom RF, et al. Validated age-specific reference values for CSF total protein levels in children. Eur J Paediatr Neurol. 2017;21:654-60.

  61. Castellazzi M, Pizzicotti S, Lombardo I, Alfiero S, Morotti A, Pellegatti P, et al. Sexual dimorphism in the cerebrospinal fluid total protein content. Clin Chem Lab Med. 2020;58:1885-90. Doi: 10.1515/cclm-2020-0419.

  62. González-Quevedo A, Peña Sánchez M, González Garcia S. Editorial on “Cerebrospinal fluid total protein reference intervals derived from 20 years of patient data”. J Lab Precis Med. 2018;3:35. Doi: 10.21037/jlpm.2018.03.12

  63. Betancourt Loza M, Peña Sánchez M, Menéndez Sainz MC, Fernández Almiral I, González-Quevedo A. Rango normal de proteínas totales en líquido cefalorraquídeo según grupos etarios y sexo. Rev Cub Neurol Neuroc. 2020;10(2):e383.




2020     |     www.medigraphic.com